Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI) - Test2 - elhamkhani - TriplyDB

Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI)

Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI)

http://www.wikidata.org/entity/Q27639338

about

Bacterial lipids: metabolism and membrane homeostasis Studies ofToxoplasma gondiiandPlasmodium falciparumenoyl acyl carrier protein reductase and implications for the development of antiparasitic agents Design and Synthesis of Aryl Ether Inhibitors of theBacillus AnthracisEnoyl-ACP Reductase Identification and Development of Novel Inhibitors of Toxoplasma gondii Enoyl Reductase Mode of Action, In Vitro Activity, and In Vivo Efficacy of AFN-1252, a Selective Antistaphylococcal FabI Inhibitor Structural and Enzymatic Analyses Reveal the Binding Mode of a Novel Series of Francisella tularensis Enoyl Reductase (FabI) Inhibitors Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis Challenges of antibacterial discovery Discovery of a novel and potent class of F. tularensis enoyl-reductase (FabI) inhibitors by molecular shape and electrostatic matching Discovery of a novel and potent class of FabI-directed antibacterial agents Identification and characterization of inhibitors of bacterial enoyl-acyl carrier protein reductase Complexomics study of two Helicobacter pylori strains of two pathological origins: potential targets for vaccine development and new insight in bacteria metabolism.Novel agents for the treatment of resistant Gram-positive infections.Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors.Is bacterial fatty acid synthesis a valid target for antibacterial drug discovery?Fatty acid biosynthesis as a target for novel antibacterials 'FAS't inhibition of malaria.Expression, purification and preliminary crystallographic analysis of the Toxoplasma gondii enoyl reductase.The Francisella tularensis FabI enoyl-acyl carrier protein reductase gene is essential to bacterial viability and is expressed during infection.NAD+ utilization in Pasteurellaceae: simplification of a complex pathway.Substituted diphenyl ethers as a broad-spectrum platform for the development of chemotherapeutics for the treatment of tularaemia The Burkholderia pseudomallei enoyl-acyl carrier protein reductase FabI1 is essential for in vivo growth and is the target of a novel chemotherapeutic with efficacy.Discrimination of potent inhibitors of Toxoplasma gondii enoyl-acyl carrier protein reductase by a thermal shift assay.Enoyl acyl carrier protein reductase inhibitors: a patent review (2006 - 2010).Recent advances in inhibitors of bacterial fatty acid synthesis type II (FASII) system enzymes as potential antibacterial agents.Studies of Staphylococcus aureus FabI inhibitors: fragment-based approach based on holographic structure-activity relationship analyses.Enoyl acyl carrier protein reductase inhibitors: an updated patent review (2011 - 2015).Benzimidazole-Based FabI Inhibitors: A Promising Novel Scaffold for Anti-staphylococcal Drug Development.AFN-1252 is a potent inhibitor of enoyl-ACP reductase from Burkholderia pseudomallei--Crystal structure, mode of action, and biological activity.Exogenous fatty acid metabolism in bacteria.Development of a triclosan scaffold which allows for adaptations on both the A- and B-ring for transport peptides.Activity of Debio1452, a FabI inhibitor with potent activity against Staphylococcus aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains.Pharmacophore and molecular docking guided 3D-QSAR study of bacterial enoyl-ACP reductase (FabI) Inhibitors.In vitro activity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics.Novel Schiff-base-derived FabH inhibitors with dioxygenated rings as antibiotic agents.Identification and characterization of the first class of potent bacterial acetyl-CoA carboxylase inhibitors with antibacterial activity.Staphylococcus aureus utilizes host-derived lipoprotein particles as sources of exogenous fatty acids.

P2860

Q26829512-34811EFE-E343-482A-B42A-6C42C5CF43E8 Q27643926-E739C646-3A29-4760-A1E2-8BBB5CC76042 Q27651378-8F27C3FC-5A3D-4EE6-A63A-4CC948295693 Q27664019-DC941B5A-4762-40FD-94ED-497FAE3FDF8B Q27671875-DB6003AA-80F3-4A96-A41F-D5CBA78BAE60 Q27679331-2CDEF4CF-CDF8-4BE7-95C6-BB122B3800F3 Q28475676-622A3231-D118-4803-8EA7-A63B02205335 Q33793074-6CD0EC94-9F79-4E42-93ED-64CD03F84C30 Q34078440-C2E329BB-EEBF-4973-A509-10EB6A527D5A Q34143489-B8919049-D4C8-4ADA-A183-2D52362464A8 Q34315832-B60C1646-712A-4915-8A31-8EB4CFEBB0AF Q35006580-089EB74B-0A9F-45B5-BD93-3BBD9BD69B77 Q35056042-4AFB1675-A4EC-4840-96A4-9F5B23B95D70 Q35216999-DD805EB9-23D7-47CE-9CA3-638CD0632D66 Q35350186-6C9C16CA-25E3-4096-95A5-3FA18D7BA0F5 Q35713880-8E78BA85-29CF-4960-9A70-EFAEA971AD20 Q35865145-71372DC5-A9DC-47DE-A9DF-98923959666A Q36459698-509B79D8-2A9E-430A-A3B0-69BD3906B222 Q36558861-4325E38B-78D0-4C38-8CF0-75485A927D8F Q36596234-7AED3990-71BA-4203-A619-AEC01CB7A329 Q37383936-E04C8898-553E-4A31-8B35-48584BC8FA70 Q37544698-9655BD45-7137-4995-A348-60E5A13FD9D0 Q37635732-B03D1373-3986-4696-9B75-C550BE66EBDF Q37886187-15563EFC-9869-4653-923C-36F6B1BC1954 Q38124842-32B0E6D1-9E18-40A0-BE31-056139502CAF Q38765020-018A0B1C-3974-4B7F-8B32-826B033AD210 Q38892242-CAC18997-1417-4409-AFDF-802ED3A96F46 Q39275601-290DE155-A8AF-49F5-AFBA-ED1C203E62D9 Q39383809-D831C018-1E99-481B-B664-02536E213B6B Q39408643-CE0EB28F-487A-4DA0-AC75-D631FB9CD623 Q39420787-D98DFFA1-9229-41A5-B298-4530A1A8541A Q39565510-CEA02862-C58E-44CB-8290-6BC491FCAEE5 Q42237853-511BA02A-B567-49D9-90F0-0C9165A7E666 Q43026765-DE3FC1DC-0AD1-4836-8991-BB5B0B1A2A00 Q46618219-8724D0B8-41F8-42CC-819D-DD4CDE9F6412 Q47811083-DBFD0BDD-C582-491D-903B-85882E3147FC Q52629550-866BA31D-ABFD-43BD-A1C6-6B199721EE54

P2860

Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI)

http://www.wikidata.org/entity/Q27639338

description

2002 nî lūn-bûn

@nan

2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI)

@ast

Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI)

@en

Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI)

@nl

type

label

Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI)

@ast

Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI)

@en

Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI)

@nl

prefLabel

Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI)

@ast

Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI)

@en

Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI)

@nl

P1433

Q27639338-0899D7F8-F3A2-4D48-9D59-7E2627053185

P1476

Q27639338-4C090C92-6F24-4B9A-B2F2-FEA239445CFB

P2093

Q27639338-04FFD09C-C7F4-425E-877C-9A4B104736D0

Q27639338-23D7F84B-364A-4539-A227-430C81D05B9A

Q27639338-2CF6F0CF-C602-46FD-8427-C2136C8FF4CE

Q27639338-305AB8DE-71BC-4871-9530-167651D3C2A3

Q27639338-3D6C2DAA-F014-4935-892E-5353FFA82210

Q27639338-49A1C662-7EF9-44E2-9B74-F87E102CC032

Q27639338-6082B141-1447-4CC3-802F-F6DDB1E25EC3

Q27639338-65E27689-19B1-4A84-8908-E56F77742A37

Q27639338-7C00D22D-085E-4960-ADED-AD07EFC999E4

Q27639338-81B73B2B-C129-4073-9B71-0B93726E993E

P304

Q27639338-894B96DF-3BF9-4005-B344-D20191BD7E68

P31

Q27639338-976B2902-A5D1-4D67-9264-C1DD57A61EBA

P356

Q27639338-240615D4-85F8-4B58-8E05-CFFBE43DF069

P407

Q27639338-58D32DFA-D895-480D-99A0-8C8861E78544

P433

Q27639338-3CE28311-15C9-4F3A-8939-2703B5B7FB7D

P478

Q27639338-1CEB8B6D-4A1A-4007-970C-BECEF30183C8

P577

Q27639338-ABC7FAE7-830C-4194-A522-D7602B2C9DC7

P698

Q27639338-0785B28F-4900-4EFA-91AF-9FE2246DD6AA

P356

P1433

Journal of Medicinal Chemistry

P1476

Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI)

@en

P2093

Brian J Polizzi

http://www.w3.org/2001/XMLSchema#string

Catherine C K Yuan

http://www.w3.org/2001/XMLSchema#string

Cheryl A Janson

http://www.w3.org/2001/XMLSchema#string

David J Payne

http://www.w3.org/2001/XMLSchema#string

Dirk A Heerding

http://www.w3.org/2001/XMLSchema#string

Irene N Uzinskas

http://www.w3.org/2001/XMLSchema#string

Kenneth A Newlander

http://www.w3.org/2001/XMLSchema#string

Mark A Seefeld

http://www.w3.org/2001/XMLSchema#string

Martha S Head

http://www.w3.org/2001/XMLSchema#string

Paul M Keller

http://www.w3.org/2001/XMLSchema#string

P304

3246-56

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/JM020050+

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

45

http://www.w3.org/2001/XMLSchema#string

P577

2002-07-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12109908

http://www.w3.org/2001/XMLSchema#string